Dr Boreham’s diagnosis:
When it comes to comparative companies, Invex’s own material avers to the ASX-listed Paradigm Biopharmaceuticals (ASXAR) and Clinuvel Pharmaceuticals (ASX:CUV).Paradigm also repurposes a blood-thinning drug for osteoarthritis pain. Paradigm is also phase II stage and has a $500m-plus market valuation.Clinuvel had orphan drug status and has achieved the holy grail of US approval for its treatment for a rare sunlight intolerance disorder. The company is now valued at more than $1bn.
Invex current market capitalization stands at $66 million.
Dr Boreham’s diagnosis:When it comes to comparative companies,...
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.012M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28219 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.6¢ | 2202 | 1 |
View Market Depth
| Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable